English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Doğan Koca, Özel İstanbul Hastanesi, Urartu 1. Sok., Van, Türkiye, Tel. 0505 689 91 97 Email. dogan.koca@deu.edu.tr Geliş Tarihi: 01.05.2015 • Kabul Tarihi: 04.03.2017 ABSTRACT Aim: We aimed to investigate the efficacy and tolerability of modified FOLFIRI-Bevacizumab (mFOLFIRI-B) regime in the secondline treatment of metastatic colorectal cancer (mCRC) patients who received oxaliplatin-based regimen in the first-line treatment.

Modified FOLFIRI-Bevacizumab Regimen in the Patients with Metastatic Colorectal Cancer Who Had Progressed After Oxaliplatin-Based Regimen